MARKET

ACHV

ACHV

Achieve Life Sciences Inc
NASDAQ
5.84
+0.05
+0.86%
After Hours: 5.84 0 0.00% 18:19 12/01 EST
OPEN
5.80
PREV CLOSE
5.79
HIGH
5.90
LOW
5.75
VOLUME
30.05K
TURNOVER
0
52 WEEK HIGH
10.30
52 WEEK LOW
2.360
MARKET CAP
123.61M
P/E (TTM)
-2.7829
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ACHV last week (1120-1124)?
Weekly Report · 6d ago
Weekly Report: what happened at ACHV last week (1113-1117)?
Weekly Report · 11/20 09:37
Weekly Report: what happened at ACHV last week (1106-1110)?
Weekly Report · 11/13 09:35
Potential Growth and Success: Jason McCarthy’s Buy Recommendation for Achieve Life Sciences Amid Promising Cytisinicline Progress
TipRanks · 11/11 15:26
Analysts Have Conflicting Sentiments on These Healthcare Companies: DENTSPLY SIRONA (XRAY), GoodRx Holdings (GDRX) and Achieve Life Sciences (ACHV)
Analysts maintain hold ratings on dentsply sirona (xray) and goodrx holdings (gdrx) and achieve life sciences (achv) in reports released today. The healthcare sector has received a lot of coverage from analysts today. Goodrx holdings and xray are both in the healthcare sector.
TipRanks · 11/10 15:41
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vor Biopharma (VOR), Gilead Sciences (GILD) and Achieve Life Sciences (ACHV)
TipRanks · 11/10 12:40
Promising Developments and Successful Trials Boost Confidence in Achieve Life Sciences: An Analysis of Michael Higgins’ Buy Rating
TipRanks · 11/10 12:11
Achieve Life Sciences Inc: Current report
Press release · 11/09 21:59
More
About ACHV
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company engaged in the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over-the-counter (OTC) products.

Webull offers Achieve Life Sciences Inc stock information, including NASDAQ: ACHV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACHV stock methods without spending real money on the virtual paper trading platform.